Skip to content

AHA/ACC 2025: high blood pressure in adults

International AHA/ACC Current

2025 AHA/ACC/Multisociety Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults

Jones DW, et al. Hypertension. 2025;82:e212–e316
DOI 10.1161/HYP.0000000000000249 · Summary checked against the source: 2026-11

Read or download the original

At a glance

  1. Overall goal: <130/80 for all adults. Make allowances for people in institutional care, with limited life expectancy, or who are pregnant. [e214]
  2. Categories are unchanged from 2017: normal, elevated, stage 1 (≥130/80) and stage 2 (≥140/90). [e222]
  3. Risk is now estimated with PREVENT, which replaces the Pooled Cohort Equations. "Increased risk" means a 10-year CVD risk of ≥7.5%. [e243]
  4. Starting drugs:
    • everyone with BP ≥140/90
    • at ≥130/80 if they have clinical CVD, diabetes, CKD or PREVENT risk ≥7.5%
    • for everyone else, if BP is still ≥130/80 after 3–6 months of lifestyle change [e243–e244]
  5. Stage 2: start two first-line drugs in a single-pill combination. [e247]
  6. Screen for primary aldosteronism in every resistant hypertension, even with a normal potassium. [e231]
  7. Use home BP monitoring with team-based care. Don't use cuffless devices or smartwatches for measurement yet. [e214]
  8. Severe hypertension (>180/120) without acute organ damage is an outpatient problem. Restart or step up oral drugs. Don't give intermittent IV boluses to inpatients. [e214, e278]

Classification

Adapted from AHA/ACC 2025 Table 4 and Table 7 [e222, e228]. Use the average of ≥2 readings on ≥2 occasions. If systolic and diastolic fall in different categories, use the higher one.

Category Office SBP Office DBP Home / daytime ABPM 24-h ABPM Night ABPM
Normal <120 and <80 <120/80 <115/75 <100/65
Elevated 120–129 and <80 – – –
Stage 1 130–139 or 80–89 ≥130/80 ≥125/75 ≥110/65
Stage 2 ≥140 or ≥90 ≥135/85 ≥130/80 ≥120/70

Diagnosis

Class 1: measure properly

  • Measure office BP with a standardised technique and record it (see the Figure 3 checklist in the original). [1, C-LD · e224]
  • In adults with hypertension, screen for secondary causes when clinical features suggest one. [1, C-EO · e231]

Class 2a: confirm out of the office

  • Untreated office BP ≥130/80 but <160/100: confirm with home or ambulatory BP to exclude white-coat hypertension before diagnosing. [2a, B-NR · e229]
  • Apparent resistant hypertension: exclude the white-coat effect with out-of-office BP. [2a, C-LD · e229]
  • An automated oscillometric device is preferred to auscultation in the office. [2a, C-EO · e224]

Class 2b: look for masked hypertension

  • Untreated office BP <130/80: out-of-office BP may be reasonable to exclude masked hypertension. [2b, B-NR · e229]

Primary aldosteronism: who to screen [e233–e234]

Class 1: screen for primary aldosteronism if any of these

  • Resistant hypertension (whatever the potassium)
  • Hypokalaemia (spontaneous or diuretic-induced)
  • Obstructive sleep apnoea
  • Adrenal incidentaloma
  • Family history of early-onset hypertension, or stroke before age 40

Screen with plasma aldosterone, renin activity and the aldosterone-to-renin ratio. Keep most antihypertensives going during screening; stop only MRAs. [1, C-LD/C-EO]

Class 2b

  • Stage 2 hypertension alone: screening for primary aldosteronism may be considered. [2b, C-EO]

Lifestyle [e239]

Class 1, LOE A: for everyone with elevated BP or hypertension

  • Weight: lose at least 5% of body weight if overweight.
  • Diet: follow a heart-healthy pattern such as DASH.
  • Sodium: <2300 mg/day, aiming for <1500 mg/day.
  • Potassium: moderate potassium intake, ideally from food (caution in CKD or with drugs that retain potassium).
  • Alcohol: abstinence is best; otherwise ≤1 drink/day for women, ≤2 for men.
  • Exercise: structured aerobic and/or resistance training.

Class 2a

  • Potassium-based salt substitutes, especially where salt is mostly added at home (not in CKD or with potassium-sparing drugs). [2a, A]

When to start drugs

flowchart TD
    BP["Patient's BP category<br/>lifestyle therapy at every level (Class 1)"] --> N["Normal<br/><120/80"]
    BP --> E["Elevated<br/>120–129 / <80"]
    BP --> S1["Stage 1<br/>130–139 / 80–89"]
    BP --> S2["Stage 2<br/>≥140/90"]
    N --> N1["Reassess in 1 year"]
    E --> E1["Reassess in 3–6 months"]
    S1 --> Q{"Clinical CVD, diabetes, CKD<br/>or PREVENT 10-yr CVD risk ≥7.5%?"}
    Q -- No --> R["Reassess in 3–6 months"]
    R --> Q2{"Still stage 1<br/>130–139 / 80–89?"}
    Q2 -- No --> R
    Q2 -- Yes --> M
    Q -- Yes --> M["BP-lowering medication<br/>AND reassess in 1 month"]
    S2 --> M
    M --> G{"BP goal met?"}
    G -- No --> I["Intensify therapy<br/>while optimising adherence"]
    I --> M
    G -- Yes --> F["Reassess in 3–6 months"]
    F --> G
Adapted from AHA/ACC 2025 Figure 7 [e270]; risk questions from Figure 6 [e245]. Every box in the original is Class 1.

Class 1: thresholds

  • All adults: start drugs at average SBP ≥140 or DBP ≥90. [1, A · e243]
  • Clinical CVD (CHD, stroke, HF): start at ≥130/80. [1, A / C-LD · e243]
  • No CVD, but diabetes, CKD or PREVENT ≥7.5%: start at ≥130/80. [1, A / C-LD · e244]
  • No CVD, PREVENT <7.5%: start if still ≥130/80 after a 3–6 month lifestyle trial. [1, B-R · e244]
  • Follow-up: after starting or changing drugs, review monthly until BP is controlled. [1, B-R · e267]

Which drugs [e247]

Class 1: first-line drugs and starting regimen

  • First-line classes: thiazide-type diuretic, long-acting dihydropyridine CCB, ACE inhibitor or ARB. [1, A]
  • Stage 2 (≥140/90): two first-line drugs from different classes, ideally in a single-pill combination. [1, B-R]

Class 2a

  • Stage 1: it's reasonable to start one first-line drug, then titrate the dose and add drugs as needed. [2a, C-EO]

Class 3: harm

  • Don't combine an ACE inhibitor, ARB and/or direct renin inhibitor. [3: Harm, A]

Targets [e252]

Class 1: increased CVD risk (PREVENT ≥7.5%, CVD, diabetes or CKD)

  • SBP <130, with encouragement towards <120. [1, A]
  • DBP <80. [1, B-R]

Class 2b: not at increased risk

  • Aiming for <130/80 (encouraging SBP <120) may be reasonable. [2b, B-NR]

Special groups

Class 1 [e257]

  • Start drugs at ≥130/80 and aim for <130/80, encouraging SBP <120. [1, A / C-LD]
  • Any first-line class works. [1, A]
  • Use an ACEi or ARB if eGFR <60 or albuminuria ≥30 mg/g. Consider one even with mild albuminuria (<30 mg/g). [1, A]

Class 1 [e215]

  • With eGFR <60 and albuminuria ≥30 mg/g, use a RAAS inhibitor (ACEi or ARB, never both) to cut CVD risk and slow CKD.

Acute ICH [e263]

  • SBP 150–220: lower straight away to 130–<140 and keep it there for at least 7 days. Stop drugs if SBP falls below 130. [2a, A]
  • Titrate smoothly and avoid swings in SBP. [2a, B-NR]

Acute ICH: harm

Acute ischaemic stroke: thrombolysis [e263]

  • Before IV thrombolysis, bring BP to <185/110, then keep it <180/105 for 24 h. [1, B-NR]
  • Correct hypotension and hypovolaemia. [1, C-LD]

Acute ischaemic stroke: no reperfusion

  • BP ≥220/120 with no thrombolysis or thrombectomy: lowering BP by 15% in the first 24 h may be reasonable. [2b, C-LD]

Acute ischaemic stroke: no benefit or harm [e264]

  • BP <220/120 with no reperfusion treatment: starting or restarting antihypertensives in the first 48–72 h doesn't help. [3: No benefit, A]
  • After successful thrombectomy, lowering SBP to <140 in the first 24–72 h worsens outcome. [3: Harm, A]

Secondary prevention [e265]

  • After ischaemic stroke, TIA or ICH: use a thiazide, ACEi or ARB, and aim for <130/80. [1, A / B-R]

Class 1 [e269]

  • Preferred drugs: labetalol and extended-release nifedipine. [1, A]
  • Counsel about low-dose aspirin (81 mg/day) to prevent preeclampsia. [1, B-R]
  • BP ≥160/110 confirmed within 15 min: treat to <160/110 within 30–60 min. [1, B-R]
  • Chronic hypertension in pregnancy: treat to <140/90. [1, B-R]

Class 3: harm

  • Avoid atenolol, ACEi, ARB, direct renin inhibitors, nitroprusside and MRAs. [3: Harm, C-LD]

Class 1 [e281]

  • Continue long-term beta-blockers through the perioperative period. [1, B-NR]

Class 2b

  • Stopping ACEi/ARB before major surgery may be considered to prevent intraoperative hypotension. [2b, B-R]
  • Elective major surgery with SBP ≥180 or DBP ≥110: deferring surgery may be considered. [2b, C-LD]

Class 3: harm

  • Don't stop beta-blockers or clonidine abruptly. Don't start a beta-blocker on the day of surgery. [3: Harm]

Resistant hypertension [e274]

flowchart TD
    A["Step 1: Confirm treatment resistance (either):<br/>office BP ≥130/80 on ≥3 drugs, or<br/>office BP <130/80 but needs ≥4 drugs<br/>(ACEi or ARB + CCB + thiazide-like preferred)"] --> B["Step 2: Exclude pseudoresistance<br/>accurate office BP · check adherence<br/>home, work or ambulatory BP for white-coat effect"]
    B --> C["Step 3: Identify and reverse contributing lifestyle factors"]
    C --> D["Step 4: Stop or minimise interfering substances<br/>(Table 11)"]
    D --> E["Step 5: Screen for secondary causes"]
    E --> F["Step 6: Drug treatment (next box)"]
    F --> G["Step 7: Refer to a specialist<br/>known or suspected secondary cause, or<br/>BP still uncontrolled after 6 months of treatment"]
Adapted from AHA/ACC 2025 Figure 8 [e276]

Step 6: drug treatment in Figure 8

  • Maximise the diuretic: replace a thiazide-type diuretic with chlorthalidone 12.5–25 mg once daily or indapamide 1.25–2.5 mg once daily.
  • Add spironolactone 25–50 mg once daily (or eplerenone 25–50 mg twice daily) if eGFR ≥45. [1, B-R · e274]
  • CKD stage 4 or worse: use chlorthalidone or a loop diuretic.
  • Add a drug with a different mechanism: beta-blocker, central sympatholytic, or non-dihydropyridine CCB if the heart rate is high.
  • Then: a dual endothelin-receptor antagonist (for example aprocitentan) or a potent vasodilator. Use hydralazine or minoxidil only if the patient is already on a beta-blocker (or bradycardic) and a loop diuretic.

Class 2a: if an MRA can't be used

  • Add one of: amiloride, a beta-blocker, an alpha-blocker, a central sympatholytic, a dual endothelin-receptor antagonist, or a direct vasodilator. [2a, B-NR · e274]

Renal denervation

  • May be reasonable for office SBP 140–180 and DBP ≥90 with eGFR ≥40 when BP stays uncontrolled despite optimal drugs, or drugs aren't tolerated. Decide with a multidisciplinary team and the patient. [2b, B-R · e274]

Hypertensive emergency [e278]

flowchart TD
    A["SBP >180 or DBP >120"] --> B{"Acute target organ damage?*"}
    B -- Yes --> E["Hypertensive emergency<br/>admit to ICU (Class 1)"]
    E --> C{"Aortic dissection or<br/>phaeochromocytoma crisis?"}
    C -- "Aortic dissection" --> AD["Reduce SBP to <120<br/>(Class 1)"]
    C -- "Phaeochromocytoma crisis" --> PH["Reduce SBP to <140<br/>in the first hour (Class 1)"]
    C -- No --> N["Reduce SBP by 25% in the first hour,<br/>to <160/100–110 over the next 6 h,<br/>then to normal over the next 24–48 h (Class 1)"]
    B -- No --> S["Severe hypertension"]
    S --> ED["Found in the emergency department:<br/>decide inpatient vs outpatient care<br/>on indications other than BP"]
    S --> OP["Found in outpatients:<br/>no need to send to the ED<br/>restart, intensify or modify oral therapy"]
    ED --> AV["AVOID parenteral BP lowering or<br/>intensified oral therapy in the acute setting<br/>(Class 3: Harm)"]
    ED --> FU["Close outpatient follow-up<br/>within 4 weeks"]
    OP --> FU
Adapted from AHA/ACC 2025 Figure 9 [e283]. *Acute target organ damage: acute HF or pulmonary oedema, neurological emergencies (PRES, encephalopathy, retinal haemorrhage, papilloedema, ICH, acute ischaemic stroke), acute coronary syndrome, acute kidney injury, acute aortic syndrome.

Figure vs recommendation text

The written recommendation is slightly different from Figure 9 in the non-compelling pathway: no more than 25% in the first hour, then <160/100 over the next 2–6 h, then 130–140 over the next 24–48 h. It also covers "other compelling conditions" beyond dissection, with SBP <140 in the first hour. [1, C-LD · e278]

Class 3: harm

  • Inpatients with severe hypertension (>180/120) but no acute organ damage: don't give intermittent IV or extra oral doses to bring BP down quickly. [3: Harm, B-NR]

What's new since 2017 [Table 1 · e215–e216]

  • PREVENT (≥7.5%) replaces the PCE (≥10% ASCVD) as the risk threshold.
  • Screening for primary aldosteronism is extended to all resistant hypertension, without needing to stop most drugs first.
  • Potassium-based salt substitutes are now recommended (2a).
  • In diabetes, ACEi/ARB moved from 2b to Class 1 when there's CKD or albuminuria.
  • New: SBP <130 is recommended to prevent mild cognitive impairment and dementia (Class 1).
  • New pregnancy recommendations: aspirin; treat ≥160/110 within 30–60 min; chronic hypertension target <140/90.
  • New renal denervation recommendations.
  • "Hypertensive urgency" is renamed severe hypertension.

Clinical pearls

  • Stage 1 starts at 130/80. Stage 2 starts at 140/90.
  • PREVENT is validated for ages 30–79.
  • The threshold for starting drugs in someone without CVD, diabetes or CKD who has low PREVENT risk is still effectively 140/90, or ≥130/80 after 3–6 months of lifestyle change.
  • Home BP of 135/85 corresponds to office 140/90. Home BP of 130/80 corresponds to office 130/80.
  • Out-of-office BP is only needed to confirm untreated readings below 160/100.

Classes and levels of evidence

How AHA/ACC 2025 grades its recommendations. Adapted from AHA/ACC 2025 Table 3 (updated December 2024) [e221]. Hover over any class or level cited on this page to see what it means.

Class Strength Meaning Wording used
Class 1 Strong Benefit >>> risk is recommended; is indicated, useful, effective or beneficial; should be performed or administered
Class 2a Moderate Benefit >> risk is reasonable; can be useful, effective or beneficial
Class 2b Weak Benefit ≥ risk may or might be reasonable; may or might be considered; usefulness is unknown, unclear or uncertain
Class 3: No benefit Moderate Benefit = risk (generally used only with level A or B) is not recommended; is not indicated, useful or effective; should not be performed or administered
Class 3: Harm Strong Risk > benefit potentially harmful; causes harm; associated with excess morbidity or mortality; should not be performed or administered
Level Meaning
Level A High-quality evidence from more than one RCT, meta-analyses of high-quality RCTs, or one or more RCTs corroborated by high-quality registry studies
Level B-R (randomised) Moderate-quality evidence from one or more RCTs, or meta-analyses of moderate-quality RCTs
Level B-NR (non-randomised) Moderate-quality evidence from one or more well-designed, well-executed non-randomised, observational or registry studies, or meta-analyses of such studies
Level C-LD (limited data) Randomised or non-randomised observational or registry studies with limitations of design or execution, meta-analyses of such studies, or physiological or mechanistic studies in humans
Level C-EO (expert opinion) Consensus of expert opinion based on clinical experience

Class (strength) and level (quality) are judged independently, so any class can pair with any level. A level C recommendation isn't necessarily weak: many important clinical questions can't be tested in trials, yet there may be clear clinical consensus.